HealthHero Acquires Digital Triage Provider Doctorlink

HealthHero, a London-based virtual care company, has acquired the digital triage platform Doctorlink for an undisclosed amount.

Doctorlink, founded in 2016, raised £20 million (~$26 million) funding in October 2017 from Eight Roads, an investment arm of Fidelity International.

The Doctorlink offerings include online triage, urgent care triage, risk assessment, and video consultations. The company’s digital triage system, which uses artificial intelligence (AI), is designed to help patients figure out what kind of care to seek.

According to the company, the triage system can help assess patients when they arrive for care and figure out if urgent care is the best course of action. The system also allows users to find a health service that suits their needs.

HealthHero plans to incorporate Doctorlink’s tech into its primary care tool.

More recently, HealthHero acquired the German medical consultation platform Fernartz.com for an undisclosed amount.

The HealthHero platform allows users to tap the medical services 24/7 through video calls, online chats, and phone calls. Patients can use the service to access a specialist, a general practitioner, a mental health clinician, or a musculoskeletal practitioner.

“This marks an exciting step for both Doctorlink and HealthHero,” Singh, CEO & co-founder of HealthHero, said in a statement. “By working together, we aim to create the gold-standard in digital primary healthcare services by combining Doctorlink’s industry-leading tech tools with our existing platform and best in breed clinical operations.”

Almost 2,000 digital health companies are acquired since 2010. A total of 132 Digital Health companies were acquired during the first nine months (9M) of 2020, according to Mercom’s latest Digital Health Funding and M&A report. In one of the largest digital health M&A transactions ever, Telehealth provider Teladoc Health has agreed to acquire Livongo Health, a developer of cellular-connected blood glucose meter and app for diabetes management, the deal valued at $18.5 billion.


RELATED POSTS